- Adjuvant Therapies for Early-Stage Breast Cancer
- CDK4/6 Inhibitors + ET in HR+ mBC: Choice of therapy and appropriate sequencing?
- Sequencing after Frontline CDK4/6: Do you continue with a CDK4/6i or switch therapy?
- Reshaping Advanced or Metastatic Breast Cancer: Antibody-Drug Conjugates (ADC)
- Real World Oncology: Translating Data to Clinical Practice
- Optimal Treatment Selection of PARP Inhibitors in Ovarian Cancer
- Antibody-Drug Conjugates in Ovarian and Cervical Cancers
- ASCO 2025 updates
OncLive® State of the Science Summit™: Women's Health
Country Music Hall of Fame
222 Rep. John Lewis Way S
Nashville, TN 37203
United States
Monday, July 14, 2025
6:00 PM-9:00 PM CDT
Complimentary Parking
In-Person Only
Event Co-Chairs
Erika Hamilton, MD
Sarah Cannon Research Institute (SCRI)
SCRI Oncology Partners
Katy Moore, MD, MS, FASCO
SCRI at Stephenson Cancer Center – University of Oklahoma
IN PARTNERSHIP WITH
OVERVIEW
OncLive® State of the Science Summit™ (SOSS) are in-person meetings designed for academic & community-based physicians and health care professionals that provide education on the science driving updates in cancer management and the associated clinical benefits for patients. SOSS attendees will improve their knowledge of novel treatment approaches and reinforce their confidence in applying state-of-the-art treatment strategies.
Registration for this Summit is complimentary.
TOPICS INCLUDE:
Venue Location
OncLive - an MJH Life Sciences brand
Copyright 2025 (C) Intellisphere, LLC
2 Commerce Drive
Cranbury, NJ 08512